Coe Jotham W, Brooks Paige R, Wirtz Michael C, Bashore Crystal G, Bianco Krista E, Vetelino Michael G, Arnold Eric P, Lebel Lorraine A, Fox Carol B, Tingley F David, Schulz David W, Davis Thomas I, Sands Steven B, Mansbach Robert S, Rollema Hans, O'Neill Brian T
Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA.
Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97. doi: 10.1016/j.bmcl.2005.08.035.
3,5-Bicyclic aryl piperidines are a new class of high-affinity alpha4beta2 nicotinic receptor agents. We have sought nicotinic receptor partial agonists of the alpha4beta2 nicotinic acetylcholine receptor for smoking cessation, and a number of compounds fulfill potency, selectivity, and efficacy requirements in vitro. In vivo, selected agents demonstrate potent partial agonist efficacy on the mesolimbic dopamine system, a key measure of therapeutic potential for smoking cessation.
3,5-双环芳基哌啶是一类新型的高亲和力α4β2烟碱受体药物。我们一直在寻找用于戒烟的α4β2烟碱型乙酰胆碱受体的烟碱受体部分激动剂,并且许多化合物在体外满足效力、选择性和功效要求。在体内,选定的药物对中脑边缘多巴胺系统显示出强效的部分激动剂功效,这是戒烟治疗潜力的关键指标。